RES-010, a non-coding RNA drug candidate designed to treat metabolic diseases.
We applied our deep understanding of metabolic diseases and the ncRNA modality to develop our lead candidate RES-010. We are advancing RES-010 toward clinical evaluation initially in obesity and fatty liver disease.
Meet our CEO Alessandro Toniolo and the Resalis team at:
JUNE 5-8, 2023
BIO International Convention, Boston
Alessandro Toniolo
Chief Executive Officer
Riccardo Panella
CSO and founder
Sakari Kauppinen
CTO and founder
Pietro Puglisi
Chairman and Investor
Michael Hodges
Scientific Advisor
Antonio Leone
Investor